Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking strategy to diabetes management. These innovative medications function by mimicking the inherent actions of GLP-1, a hormone produced by the gut in response to consumption. By triggering GLP-1 receptors in the pancreas, these substances boost insulin release and inhib

The burgeoning landscape of novel treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting substantial weight reduction – they exhibit intriguing contrasts in their